Leflunomide in the treatment of refractory primary nephrotic syndrome

As a novel immunosuppressant, LEF has been included in the first-line drug for the treatment of rheumatoid arthritis. LEF can inhibit lymphocyte proliferation. In recent years, it has been increasingly used in the treatment of other autoimmune diseases and kidney disease. Leflunomide treatment refractory primary nephrotic syndrome meta-analysis shows that leflunomide combined with glucocorticoid treatment to reduce proteinuria and serum albumin, and may have promote RPNS renal function in patients recovery. There are efficacy differences among Leflunomide for different types of pathology. Mesangial proliferative and membrane nephropathy minimal change in general or most effective, however, the proliferative glomerulonephritis focal segmental glomerulosclerosis and film only a few, and the results are less than ideal. The adverse reactions of Leflunomide can be tolerated. LEF is recommended as second-line combination. The fewer such research remains to be further confirmed.